截至2024年6月30日止六个月，收入减少乃由于2023年同期就许可协议项下 CMG901的对外授权确认许可收入约人民币1.095亿元(包括一次性预付款)，而报告期内就里程碑付款及技术转让服务确认的收入为约人民币2070万元，部分被普佑恒 (普特利单抗注射液)销售翻倍收入及确认提供CDMO服务收入约人民币1780万元(截至2023年6月30日止六个月：零)所抵销。Le Pu Biosciences-B (02157) fell more than 3% after the performance release. As of the time of publication, it fell by 3.46%, to HKD 2.23, with a turnover of 5.6623 million HKD.
According to the Zhitong Finance APP, Le Pu Biosciences-B (02157) fell more than 3% after the performance release. As of the time of publication, it fell by 3.46%, to HKD 2.23, with a turnover of 5.6623 million HKD.
On the news front, Le Pu Biosciences-B released its six-month performance ending June 30, 2024, with revenue of 0.133 billion yuan (RMB, the same below), a year-on-year decrease of 13.2%; the company's shareholders' loss amounted to 0.192 billion yuan, a year-on-year expansion of 35.6%; basic loss per share was 0.12 yuan.
In the six months ended June 30, 2024, the decrease in revenue was due to the recognition of external authorization licensing revenue of approximately RMB 0.1095 billion (including one-time prepayment) for CMG901 under the license agreement in the same period of 2023, while the revenue recognized for milestone payments and technology transfer services during the reporting period was approximately RMB 20.7 million. Part of it was offset by the doubled revenue from the sale of Puyuheng (Puterli Monoclonal Antibody Injection) and the confirmed revenue of approximately RMB 17.8 million from providing CDMO services (six months ended June 30, 2023: zero).
